Evidence map›Paper›PMID 36427174›Full record

Trial reportJournal of autism and developmental disorders2024

Efficacy of Sulforaphane in Treatment of Children with Autism Spectrum Disorder: A Randomized Double-Blind Placebo-Controlled Multi-center Trial.

Jianjun Ou, Robert C Smith, Russell H Tobe, Jingjing Lin, Jen Arriaza, Jed W Fahey, Ruiting Liu, Ying Zeng, Yanan Liu, Lian Huang and 8 more

Abstract readRandomized Controlled TrialMulticenter Study
PubMed Publisher
In one paragraph

Trial report in Journal of autism and developmental disorders, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed, 2 pooled it
2.6field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 2 syntheses or guidelines pooled it, 23 citations in OpenAlex.

  1. Pooled it
  2. Complementary and Alternative Medicine for Autism - A Systematic Review.Journal of autism and developmental disorders · 2025
    Pooled it
  3. Trial
  4. Article
  5. Review
  6. Review
  7. Article
  8. Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Review
  16. Article
  17. Review
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 8 institutions in 2 countries.

Jianjun Ou *Department of Psychiatry, National Clinical Research Center for Mental Disorders, The Second Xiangya Hospital of Central South University, Middle Renmin Road, Changsha, 410011, Hunan, China.ORCID http://orcid.org/0000-0002-0611-7715
Robert C Smith *Nathan S. Kline Institute for Psychiatric Research, Orangeburg, NY, USA.
Russell H TobeNathan S. Kline Institute for Psychiatric Research, Orangeburg, NY, USA.
Jingjing LinDepartment of Psychiatry, National Clinical Research Center for Mental Disorders, The Second Xiangya Hospital of Central South University, Middle Renmin Road, Changsha, 410011, Hunan, China.
Jen ArriazaSchool of Professional Studies, New York University, New York, NY, USA.
Jed W FaheyDepartments of Medicine, Psychiatry and Behavioral Sciences, and Pharmacology & Molecular Sciences, Johns Hopkins University, Baltimore, MD, USA.
Ruiting LiuDepartment of Psychiatry, National Clinical Research Center for Mental Disorders, The Second Xiangya Hospital of Central South University, Middle Renmin Road, Changsha, 410011, Hunan, China.
Ying ZengDepartment of Psychiatry, National Clinical Research Center for Mental Disorders, The Second Xiangya Hospital of Central South University, Middle Renmin Road, Changsha, 410011, Hunan, China.
Yanan LiuDepartment of Psychiatry, National Clinical Research Center for Mental Disorders, The Second Xiangya Hospital of Central South University, Middle Renmin Road, Changsha, 410011, Hunan, China.
Lian HuangDepartment of Psychiatry, National Clinical Research Center for Mental Disorders, The Second Xiangya Hospital of Central South University, Middle Renmin Road, Changsha, 410011, Hunan, China.
Yidong ShenDepartment of Psychiatry, National Clinical Research Center for Mental Disorders, The Second Xiangya Hospital of Central South University, Middle Renmin Road, Changsha, 410011, Hunan, China.
Yamin LiDepartment of Psychiatry, National Clinical Research Center for Mental Disorders, The Second Xiangya Hospital of Central South University, Middle Renmin Road, Changsha, 410011, Hunan, China.
Daomeng ChengThe Affiliated Brain Hospital of Guangzhou Medical University, Guangzhou, 510370, Guangdong, China.
Brian CornblattNutramax Laboratories, Consumer Care, Inc., Edgewood, MD, USA.
John M DavisDepartment of Psychiatry, University of Illinois, Psychiatric Institute, Chicago, IL, USA.
Jingping ZhaoDepartment of Psychiatry, National Clinical Research Center for Mental Disorders, The Second Xiangya Hospital of Central South University, Middle Renmin Road, Changsha, 410011, Hunan, China. zhaojingping@csu.edu.cn.
Renrong WuDepartment of Psychiatry, National Clinical Research Center for Mental Disorders, The Second Xiangya Hospital of Central South University, Middle Renmin Road, Changsha, 410011, Hunan, China. wurenrong@csu.edu.cn.
Hua JinDepartment of Psychiatry, University of California San Diego and Psychiatric Service, VA San Diego Healthcare System, San Diego, CA, USA. hjin@health.ucsd.edu.
Central South University · CNNathan Kline Institute for Psychiatric Research · USGuangdong 999 Brain Hospital · CNJohns Hopkins University · USNew York University · USNutramax Laboratories (United States) · USUC San Diego Health System · USUniversity of Illinois Urbana-Champaign · US

Funding

National Key R&D Program of China 2016YFC1306900National Natural Science Foundation of China 81622018National Natural Science Foundation of China 81974217Natural Science Foundation of Hunan Province 2020JJ5825
6 · The paper itself

Abstract

Sulforaphane has been reported to possibly improve core symptoms associated with autism spectrum disorders from mostly small size studies. Here we present results of a larger randomized clinical trial (N = 108) in China. There were no significant changes in caregiver rated scales between sulforaphane and placebo groups. However, clinician rated scales showed a significant improvement in the sulforaphane group, and one third of participants showed at least a 30% decrease in score by 12 weeks treatment. The effects of sulforaphane were seen across the full range of intelligence and greater in participants over 10 years. Sulforaphane was safe and well-tolerated even for young children. The inconsistent results between caregiver and clinician rated scales suggest more clinical trials are needed to confirm our findings.

Indexed as

Autism Spectrum DisorderChildChild, PreschoolDouble-Blind MethodHumansIsothiocyanatesSulfoxidesTreatment OutcomeIsothiocyanatessulforaphaneSulfoxidesAutism spectrum disorders (ASD)Clinic trialsCognitive impairmentSulforaphane

Identifiers

PMID36427174
OpenAlexW4310080468

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.